Human IL-27 ELISA Kit (Interleukin-27) (ab83695)


  • 製品名Human IL-27 ELISA Kit (Interleukin-27)
    IL27 キット 製品一覧
  • 検出方法Colorimetric
  • 再現性
    サンプル N 平均値 SD CV%
    A 9 343pg/ml 12.9 4.8%
    B 9 127pg/ml 8.1 5.1%
    C 9 427pg/ml 15.8 3.8%
    サンプル N 平均値 SD CV%
    A 9 343pg/ml 29 8.5%
    B 9 157pg/ml 17 10.8%
    C 9 427pg/ml 38 9%
  • テスト
    1 x 96 well plate
  • サンプルの種類
    Cell culture supernatant, Serum, Plasma
  • アッセイタイプSandwich (quantitative)
  • 検出感度
    < 12.8 pg/ml
  • 検出範囲
    31.25 pg/ml - 1000 pg/ml
  • 添加回収試験

    95 %

  • 全工程の試験時間
    3h 45m
  • ステップMultiple steps standard assay
  • 種交差性
    交差種: Human
  • 製品の概要

    Abcam’s IL-27 (Interleukin-27) Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of IL-27 in Human serum, plasma, buffered solutions and cell culture medium.

    A monoclonal antibody specific IL-27 has been coated onto the wells of the microtiter strips provided. Samples, including standards of known IL-27 concentrations, control specimens or unknowns are pipetted into these wells. During the first incubation, the standards or samples and a biotinylated monoclonal antibody specific for IL-27 are simultaneously incubated. After washing, the enzyme Streptavidin-HRP, that binds the biotinylated antibody is added, incubated and washed. A TMB substrate solution is added which acts on the bound enzyme to induce a colored reaction product. The intensity of this colored product is directly proportional to the concentration of IL-27 present in the samples. 

    This kit will recognize both endogenous and recombinant Human IL-27.

  • アプリケーション適用あり: Sandwich ELISAmore details
  • 試験プラットフォームMicroplate


  • 機能Cytokine with pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL-27 subunit p28 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replivation.
  • 組織特異性Expressed in monocytes and in placenta.
  • 配列類似性Belongs to the IL-6 superfamily.
  • 翻訳後修飾O-glycosylated.
  • 細胞内局在Secreted. Does not seem to be secreted without coexpression of EBI3.
  • Information by UniProt
  • 別名
    • IL 27A
    • IL 30
    • IL-27 subunit alpha
    • IL-27-A
    • IL27
    • IL27-A
    • IL27A
    • IL27A_HUMAN
    • IL27p28
    • IL30
    • Interleukin 27
    • Interleukin 27 subunit alpha
    • Interleukin 30
    • Interleukin-27 subunit alpha
    • p28
    see all
  • 参照データベース


Our Abpromise guarantee covers the use of ab83695 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Sandwich ELISA Use at an assay dependent concentration.

Human IL-27 ELISA Kit (Interleukin-27) 画像

  • Representative Standard Curve using ab83695


Human IL-27 ELISA Kit (Interleukin-27) (ab83695) 使用論文

ab83695 has not yet been referenced specifically in any publications.

Product Wall

IL27 human macrophage secretion on day 3

Excellent Excellent 5/5 (Ease of Use)
IL27 secretion by human macrophages isolated by negative selection in culture for 3 days.
Kit easy to use, the assay takes about 6hr, good specificity as shown by higher secretion by M1 macrophages (MSCF+IFNg) compared to the others subtypes (M0=MCSF M2=MSCF+IL4 DEX=MCSF+Dexamethasone TGFb=MCSF+TGFb)

Abcam user community

Verified customer

投稿 Apr 08 2014

Thank you for contacting us.

I have been in contact with the lab regarding this. A total recombinant protein has been used for immunization. These antibodies can either recognize free p28 or p28 binded to EBI3. We know that they do not r...

Read More

Hello. Regarding your follow up questions, the IL-35 comes from an outside supplier and the clone B-G44 is not available for purchase from our catalog separately from the kit.

Our internal protocol for DC activation is the following :

Read More